Lactadherin inhibits enzyme complexes of blood coagulation by competing for phospholipid-binding sites
- 1 April 2003
- journal article
- Published by American Society of Hematology in Blood
- Vol. 101 (7) , 2628-2636
- https://doi.org/10.1182/blood-2002-07-1951
Abstract
Lactadherin, a glycoprotein of the milk-fat globule membrane, contains tandem C domains with homology to discoidin-type lectins and to membrane-binding domains of blood-clotting factors V and VIII. We asked whether the structural homology confers the capacity to compete for the membrane-binding sites of factor VIII and factor V and to function as an anticoagulant. Our results indicate that lactadherin competes efficiently with factor VIII and factor V for binding sites on synthetic phosphatidylserine-containing membranes with half-maximal displacement at lactadherin concentrations of 1 to 4 nM. Binding competition correlated to functional inhibition of factor VIIIa–factor IXa (factor Xase) enzyme complex. In contrast to annexin V, lactadherin was an efficient inhibitor of the prothrombinase and the factor Xase complexes regardless of the degree of membrane curvature and the phosphatidylserine content. Lactadherin also inhibited the factor VIIa–tissue factor complex efficiently whereas annexin V was less effective. Because the inhibitory concentration of lactadherin was proportional to the phospholipid concentration, and because lactadherin was not an efficient inhibitor in the absence of phospholipid, the major inhibitory effect of lactadherin relates to blocking phospholipid sites rather than forming inhibitory protein-protein complexes. Lactadherin was also an effective inhibitor of a modified whole blood prothrombin time assay in which clotting was initiated by dilute tissue factor; 60 nM lactadherin prolonged the prothrombin time 150% versus 20% for 60 nM annexin V. These results indicate that lactadherin can function as a potent phospholipid-blocking anticoagulant.Keywords
This publication has 66 references indexed in Scilit:
- Production of large unilamellar vesicles by a rapid extrusion procedure. Characterization of size distribution, trapped volume and ability to maintain a membrane potentialPublished by Elsevier ,2002
- Four Hydrophobic Amino Acids of the Factor VIII C2 Domain Are Constituents of Both the Membrane-binding and von Willebrand Factor-binding MotifsJournal of Biological Chemistry, 2002
- Unsaturated Phospholipid Acyl Chains Are Required To Constitute Membrane Binding Sites for Factor VIIIBiochemistry, 1998
- Anti-beta2-glycoprotein I (beta2GPI) monoclonal antibodies with lupus anticoagulant-like activity enhance the beta2GPI binding to phospholipids.Journal of Clinical Investigation, 1997
- Cloning and Sequence Analysis of Human Breast Epithelial Antigen BA46 Reveals an RGD Cell Adhesion Sequence Presented on an Epidermal Growth Factor-Like DomainDNA and Cell Biology, 1996
- Annexin V Inhibition of Factor IXa-Catalyzed Factor X Activation on Human Platelets and on Negatively-Charged Phospholipid VesiclesBiochemistry, 1996
- Prothrombin activation on dioleoylphosphatidylcholine membranesEuropean Journal of Biochemistry, 1994
- Phospholipid vesicle formation using nonionic detergents with low monomer solubility. Kinetic factors determine vesicle size and permeabilityBiochemistry, 1984
- Changes in membrane phospholipid distribution during platelet activationBiochimica et Biophysica Acta (BBA) - Biomembranes, 1983
- Diffusion of univalent ions across the lamellae of swollen phospholipidsJournal of Molecular Biology, 1965